Next Generation Sequencing
Next Generation Sequencing (NGS) is an innovative technology that has revolutionized oncology research. Specifically, with NGS technology researchers are able to quickly sequence all exons in a genome (Whole Exome Sequencing or WES) and utilize RNA sequencing (RNAseq) to discover novel RNA variants and quantify mRNA for differential gene expression analysis.
Champions Oncology provides Next Generation Sequencing as an endpoint for in vivo and ex vivo studies. Tissue processing post study completion at our US-based facilities, provides fast turnaround times with reliable, high quality data analysis provided through Lumin Workspaces and visualization using Lumin Bioinformatics.
RNAseq Platform
Illumina Nextseq2000
Configuration: 2x50 bp
Depth: 50M paired end reads
WES Platform
Illumina Nextseq2000
Configuration: 2x100 bp
Depth: 100X mean depth
As oncology experts, our team has deep scientific competencies to not only aid in the planning of your upcoming in vivo or ex vivo study, but to recommend NGS endpoint analyses that can help you discover endless insights with your therapeutic candidate from our highly characterized tumor bank.
- Differential Gene Expression
- Normalization
- Fusion Identification
- SNV/Indel Calling
- WES Copy Number
- HLA Typing
- Mutation Filtering & Annotations
